| Trial ID: | L0293 |
| Source ID: | NCT05203237
|
| Associated Drug: |
VK2735
|
| Title: |
Phase 1 Study to Evaluate the Safety and Tolerability of VK2735
|
| Acronym: |
--
|
| Status: |
Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
NASH - Nonalcoholic Steatohepatitis
|
| Interventions: |
Biological: VK2735|Biological: Placebo
|
| Outcome Measures: |
Incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious AEs (TESAEs)|Evaluate the Pharmacokinetic profile of VK2735
|
| Sponsor/Collaborators: |
Viking Therapeutics, Inc.
|
| Gender: |
All
|
| Age: |
18 Years to 65 Years ?? (Adult, Older Adult)
|
| Phases: |
Phase 1
|
| Enrollment: |
88
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
|
| Start Date: |
December 14, 2021
|
| Completion Date: |
December 2022
|
| Results First Posted: |
--
|
| Last Update Posted: |
February 4, 2022
|
| Locations: |
Viking Clinical Site, Adelaide, South Australia, Australia
|
| URL: |
https://ClinicalTrials.gov/show/NCT05203237
|
